- Home
- MKZR vs RLYB Comparison
MKZR vs RLYB Comparison
Compare MKZR & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- RLYB
- Stock Information
- Founded
- MKZR 2012
- RLYB 2018
- Country
- MKZR United States
- RLYB United States
- Employees
- MKZR N/A
- RLYB N/A
- Industry
- MKZR
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- MKZR
- RLYB Health Care
- Exchange
- MKZR Nasdaq
- RLYB Nasdaq
- Market Cap
- MKZR 14.0M
- RLYB 14.4M
- IPO Year
- MKZR N/A
- RLYB 2021
- Fundamental
- Price
- MKZR $0.88
- RLYB $0.40
- Analyst Decision
- MKZR
- RLYB Hold
- Analyst Count
- MKZR 0
- RLYB 3
- Target Price
- MKZR N/A
- RLYB $15.00
- AVG Volume (30 Days)
- MKZR 57.9K
- RLYB 240.7K
- Earning Date
- MKZR 05-15-2025
- RLYB 05-08-2025
- Dividend Yield
- MKZR 23.39%
- RLYB N/A
- EPS Growth
- MKZR N/A
- RLYB N/A
- EPS
- MKZR N/A
- RLYB N/A
- Revenue
- MKZR $23,037,348.00
- RLYB $848,000.00
- Revenue This Year
- MKZR N/A
- RLYB N/A
- Revenue Next Year
- MKZR N/A
- RLYB N/A
- P/E Ratio
- MKZR N/A
- RLYB N/A
- Revenue Growth
- MKZR 52.64
- RLYB N/A
- 52 Week Low
- MKZR $0.79
- RLYB $0.22
- 52 Week High
- MKZR $5.50
- RLYB $1.73
- Technical
- Relative Strength Index (RSI)
- MKZR N/A
- RLYB 59.92
- Support Level
- MKZR N/A
- RLYB $0.27
- Resistance Level
- MKZR N/A
- RLYB $0.49
- Average True Range (ATR)
- MKZR 0.00
- RLYB 0.06
- MACD
- MKZR 0.00
- RLYB 0.01
- Stochastic Oscillator
- MKZR 0.00
- RLYB 57.34
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.